Bonnie Erbe’s “To The Contrary” program on PBS will be airing a three-part series on genetic technologies and their impact in diagnosing rare disease, beginning this week. The series will describe the evolution of DNA sequencing and show how DNA may be an effective tool in understanding diseases. Part 1 of the series begins Jan. [...]
Filed under: Finding Cures | Tagged: biotech, biotechnology | Leave a Comment »
We are looking for biotech humanitarians for our annual Biotech Humanitarian Award. The award recognizes an everyday hero who has helped to heal, fuel or feed the planet through their work in biotechnology. Know someone that you feel should be recognized for their good works? Nominate someone at www.iambiotech.org/award through January 31, 2010.
2009 Biotech Humanitarian Dr. [...]
Filed under: 2010 BIO International Convention, Award, BIO, Finding Cures | Tagged: BIO, biotech, biotechnology, Innovation | Leave a Comment »
A two-time cancer survivor and a perennial Republican swing voter, Senator Arlen Specter (R-PA), urged the creation of the Cures Acceleration Network, a new agency to provide grants to help biotech companies develop new treatments, reports Reuters and The Boston Globe:
I believe that we can live not only longer lives, but healthier lives, by harnessing [...]
Filed under: Congress, Finding Cures, In the News, Uncategorized | Tagged: Cures Acceleration Network, Specter | Leave a Comment »
The Parkinson’s Action Network sent this to us for our blog:
The Parkinson’s Action Network and RetireSafe, along with 58 other organizations sent a letter to Congress urging them to take action on the SBIR Reauthorization Act this Congressional session. The Parkinson’s Action Network recognizes the unique needs of small biotechnology companies and that shrinking the [...]
Filed under: Congress, Finding Cures, SBIR, patient groups | Tagged: Congress, Parkinson's Action Network, SBIR | Leave a Comment »
Welcome Back Senators! We hope you enjoyed your recess.
There is buzz that SBIR may make it on to the Senate calendar this session, but we do not have a definite date just yet. Stay tuned!
This act will increase access to early-stage funding for treatments and cures for debilitating diseases. With so many new treatments [...]
Filed under: Congress, Finding Cures, SBIR | Tagged: SBA, SBIR, Senate | Leave a Comment »
The feature story in the July 2008 Oncology Business Review is “On-Conversation with Michael Weingarten, Director, Small Business Innovation Research program (SBIR), Office of the Director, National Cancer Institute.”
NOTE: We have highlighted a few of Weingarten’s answers below. Please follow the links for the full interview.
OBR: HOW HAS THIS PROGRAM BEEN ADMINISTERED TO THIS [...]
Filed under: Finding Cures, SBIR, venture capital | Tagged: Cancer, Michael Weingarten, NIH, Phase I, SBIR, venture capital | Leave a Comment »
Hopes and Cures spokes to John Risner, President of The Children’s Tumor Foundation about the group’s work, in particular about funding for research. CTF is a non-profit 501(c) (3) medical foundation, dedicated to improving the health and well being of individuals and families affected by the neurofibromatosis (NF).
ABOUT NF
Neurofibromatosis (NF) is the term for [...]
Filed under: Finding Cures, SBIR, patient groups, venture capital | Tagged: CCF, children's tumor Foundation, Drug Discovery, NF, research, Tumors, VC | 2 Comments »
Alzheimer’s Drug Discovery Foundation
A new way to look at funding
The Alzheimer’s Drug Discovery Foundation (ADDF) raises money and awards grants to academic and biotechnology industry scientists who are conducting drug discovery research for Alzheimer’s Disease, related dementias and cognitive aging.
The way research is funded is evolving and by employing a venture capital model, [...]
Filed under: Finding Cures, SBIR, patient groups, venture capital | Tagged: Allon, Alzheimer's disease, Comentis, Estee Lauder, Fillit, SBIR | Leave a Comment »
California Biotech Law Blog posted a summary of recent House hearings on reauthorizing the Small Business Innovation Research Program (SBIR).
In the world of biotechnology, the principle at stake is the United States’s claim to be an innovation engine in the global economy. Our members and their scientists are developing disease treatments and cures at a rapid rate, but because these cutting-edge treatments are so new, it takes 10-15 years before they reach the market. In the meantime, they thrive on traditional venture capital and the government’s version of VC: the SBIR program.
If Congress wants to perpetuate the image – and reality – of the US as the center of innovation, they must adapt the criteria for SBIR grants to match the reality for these budding treatments and burgeoning companies.
Filed under: BIO, Congress, Finding Cures, SBIR, venture capital | Tagged: biotech, MS, Parkinson's, SBIR | Leave a Comment »
